Liquid biopsy creating fastest-growing targeted sequencing segment — the commercial development of targeted next-generation sequencing of cell-free DNA (cfDNA) in blood — enabling non-invasive detection of somatic tumor mutations, copy number alterations, and gene fusions from circulating tumor DNA (ctDNA) shed by tumors into the bloodstream — creating a clinical testing modality that addresses tissue biopsy's limitations (inaccessible tumors, insufficient material, spatial sampling bias) while enabling longitudinal treatment monitoring through serial blood sampling, with the Targeted DNA/RNA Sequencing Market experiencing liquid biopsy as its most commercially dynamic segment whose expanding clinical applications and regulatory approvals progressively justify premium pricing.

Guardant Health's liquid biopsy commercial leadership — Guardant Health's Guardant360 CDx — the first FDA-approved liquid biopsy comprehensive genomic profiling test with multiple companion diagnostic designations — generating approximately $600 million in annual revenue and demonstrating the commercial viability of clinical liquid biopsy as a billion-dollar market opportunity. Guardant360's companion diagnostic designations — including osimertinib in EGFR mutation-positive NSCLC, rucaparib in BRCA-mutated ovarian cancer, and multiple additional therapy-matching designations — creating mandatory clinical utilization pathways that sustain commercial volume from guideline-driven oncologist ordering patterns.

Minimal residual disease liquid biopsy — the growing MRD (minimal residual disease) market — where ultra-sensitive ctDNA detection following curative-intent surgery or chemotherapy identifies patients with residual disease at risk for recurrence — creating a new clinical testing paradigm in breast cancer, colorectal cancer, and lung cancer whose clinical validation in multiple disease settings is progressively establishing commercial utility.

Grail's Galleri multi-cancer early detection — Grail's (Illumina subsidiary) Galleri test — using methylation-based cfDNA analysis to detect and localize over fifty cancer types from a single blood draw — representing the most commercially ambitious liquid biopsy application whose multi-cancer early detection potential could create the largest addressable market in diagnostic medicine if clinical validation trials demonstrate mortality reduction. The PATHFINDER study and NHS-Galleri trial investigating Galleri's population screening performance — with anticipated results defining whether multi-cancer liquid biopsy screening achieves clinical utility standards required for broad guideline adoption and payer coverage.

As liquid biopsy platforms demonstrate expanding clinical utility across treatment selection, MRD monitoring, and potential early cancer detection, how should the oncology community develop evidence standards specifically designed for liquid biopsy clinical validation — accounting for the unique challenges of ctDNA biology (tumor shedding variability, clonal hematopoiesis interference, tumor heterogeneity sampling) that differentiate liquid biopsy validation from tissue-based biomarker validation frameworks?

FAQ

How is targeted sequencing applied in hereditary disease and rare disease diagnosis? Targeted sequencing in hereditary and rare disease: hereditary cancer: germline panel: BRCA1/2; PALB2; ATM; CHEK2; RAD51C; RAD51D; Lynch: MLH1; MSH2; MSH6; PMS2; EPCAM; APC; MUTYH; comprehensive: 80+ genes; panel: indication-specific; specific panels: hereditary breast/ovarian: primary; colorectal: Lynch + polyposis; hereditary paraganglioma: SDHB/C/D; MEN: RET; VHL; rare disease diagnosis: whole exome: broader: expensive; targeted gene panel: cost-effective: known: phenotype; neurology: epilepsy gene panel: SCN1A; KCNQ2; +100 genes; cardiomyopathy panel: MYH7; MYBPC3; TTN; PKP2; +50 genes; pulmonary: cystic fibrosis: CFTR; channelopathy: KCNQ1; KCNH2; HCM: MYBPC3: MYH7; retinal dystrophy: RPE65; RPGR; comprehensive; platform: Illumina: dominant; Thermo Ion Torrent: PGM: alternative; bioinformatics: challenging: variant interpretation; VUS: uncertain significance: significant; ACMG: variant classification: 5-tier: pathogenic: VUS: benign; laboratory: interpretation: critical: expert; clinical utility: inherited cancer: germline: established; ClinVar: public database; growing; commercial: Myriad Genetics; Ambry; Invitae; Color Genomics; GeneDx; competition: price: declining; panel: expanding; market: hereditary cancer: $2B+; rare disease: growing; clinical: established; market dynamics: consolidation: major labs.

What bioinformatics and software components drive the targeted sequencing market? Bioinformatics market in targeted sequencing: sequencing workflow: raw reads (FASTQ) → alignment (BAM) → variant calling (VCF) → annotation → reporting; software components: alignment: BWA; BOWTIE2: open source; proprietary: cloud-based; variant calling: GATK: gold standard; open source; commercial: proprietary; annotation: VarSeq (Golden Helix); Franklin (Genoox); Fabric: databases: ClinVar; ClinGen; OMIM; gnomAD; COSMIC: oncology; commercial: OncoKB; CGI; annotation: annotation source: commercial or academic; interpretation: MDM/LIMS: laboratory information management; Softgenetics: NextGENe; Agilent Alissa Interpret; Illumina BaseSpace; Strand NGS; reporting: template: automated: report generation; clinical: interpretation: manual + AI; AI interpretation: growing; FDA: SaMD: AI: regulatory; laboratory informatics: LIMS: Labvantage; Nautilus; cloud: AWS; Azure; storage: significant: NGS data volume; specific platforms: Illumina BaseSpace: instrument connected; cloud; Complete Genomics (BGI): analysis; Roche NAVIFY: oncology; clinical; market: bioinformatics: $1-2B: growing; instrument: linked; clinical: interpretation: highest value; AI: growing: interpretation; cloud: growing: storage + compute; market: bioinformatics: specialty; clinical: interpretation: highest barrier; regulatory: AI: SaMD: growing constraint; commercial: significant: recurring: subscription.

#TargetedDNARNASequencingMarket #LiquidBiopsy #ctDNASequencing #MRDtesting #GuardantHealth #MultiCancerEarlyDetection